伦敦生物技术初创公司Baseimmune近日宣布，其在A轮融资中成功筹集了1130万美元（约900万英镑）的资金，这将加速公司利用人工智能技术设计和开发疫苗的进程。此次融资活动得到了众多知名投资者的超额认购，其中包括MSD Global Health Innovation Fund、IQ Capital，以及早期投资者Hoxton Ventures、Creator Fund、Beast Ventures和Maki.vc。
Baseimmune公司以其创新的机器学习平台著称，该平台旨在简化并优化疫苗设计的复杂过程。通过利用人工智能的力量，Baseimmune有望革新疫苗研发领域，提高疫苗开发的效率和成功率，为全球公共卫生提供更有力的支持。
此次A轮融资的成功，不仅为Baseimmune带来了财务上的支持，也为其科研和技术发展注入了新的活力。投资者的广泛参与和超额认购显示出市场对Baseimmune技术潜力和未来前景的强烈信心。Baseimmune表示，将利用这笔资金进一步推动其人工智能技术的研发，加速疫苗项目的临床试验，并扩大其在全球的影响力。
Baseimmune的这一里程碑标志着生物技术与人工智能结合的又一重大进展，预示着未来疫苗开发可能实现更快、更精准的创新模式。随着全球公共卫生挑战的日益增加，Baseimmune的技术有望在应对传染病和全球健康危机中发挥关键作用。
英语如下：
**News Title:** “London Biotech Firm Baseimmune Secures $11.3M Investment, AI Vaccine Design Platform Garners Attention”
**Keywords:** Baseimmune, AI疫苗, $11.3M Funding
**News Content:** London-based biotech startup Baseimmune recently announced that it has successfully raised $11.3 million (approximately £9 million) in its Series A funding round, which will expedite the company’s use of artificial intelligence in vaccine design and development. The financing round saw strong oversubscription from a number of prominent investors, including MSD Global Health Innovation Fund, IQ Capital, as well as early backers Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc.
Renowned for its innovative machine learning platform, Baseimmune aims to streamline and optimize the complex process of vaccine design. By leveraging the power of AI, the company aspires to revolutionize the vaccine research and development landscape, enhancing efficiency and success rates, and providing stronger support for global public health.
The successful Series A funding not only bolsters Baseimmune financially but also infuses new momentum into its research and technological advancement. The wide participation of investors and the oversubscription demonstrate a strong market confidence in Baseimmune’s technological potential and future prospects. The company intends to utilize the funds to further advance its AI technology, accelerate clinical trials for vaccine projects, and expand its global reach.
This milestone for Baseimmune signifies another significant advancement in the convergence of biotechnology and AI, foreshadowing a potentially faster and more precise innovation model for future vaccine development. As global public health challenges escalate, Baseimmune’s technology is poised to play a crucial role in addressing infectious diseases and global health crises.
【来源】https://www.maginative.com/article/baseimmune-closes-11-3m-series-a-to-accelerate-ai-designed-vaccines/
Views: 1